Lung Non-Small Cell Carcinoma — Research

Lung Non-Small Cell Carcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	84,720	`("Carcinoma, Non-Small-Cell Lung"[mh] OR "Lung Carcinoma, Non-Small-Cell"[mh] OR "Nonsmall Cell Lung Cancer"[mh])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	26,886	`("Carcinoma, Non-Small-Cell Lung"[mh] OR "Lung Carcinoma, Non-Small-Cell"[mh] OR "Nonsmall Cell Lung Cancer"[mh]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	4,343	`("Carcinoma, Non-Small-Cell Lung"[mh] OR "Lung Carcinoma, Non-Small-Cell"[mh] OR "Nonsmall Cell Lung Cancer"[mh]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (372)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 151–175 of 372 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
· Clin Cancer Res · 2013 · PMID 23470965 · validated civic_curation pubmed
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
· Lancet Oncol · 2011 · PMID 21933749 · validated civic_curation pubmed
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer.
· N Engl J Med · 2015 · PMID 26466010 · validated civic_curation pubmed
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.